Halozyme Therapeutics Appoints David Ramsay as Interim CFO Amid Executive Search

Halozyme Therapeutics Appoints David Ramsay as Interim CFO

Halozyme Therapeutics, Inc. announces the appointment of David Ramsay as Interim Chief Financial Officer (CFO), a decision that looks to bolster the company during its search for a permanent CFO. Ramsay, who has over 30 years of financial leadership experience in the biotechnology and life sciences sectors, previously held the CFO position at Halozyme from 2003 to 2009 and again from 2013 to 2015. His tenure significantly contributed to the company's transformation from a private entity to a billion-dollar biopharmaceutical firm. Ramsay's return is expected to provide continuity and a wealth of expertise as Halozyme navigates ongoing strategic initiatives.

Dr. Helen Torley, Halozyme's President and CEO, expresses strong enthusiasm about Ramsay's reappointment, highlighting his deep understanding of the company and his proven track record in capital markets as critical assets. His prior leadership established a solid foundation for the company's financial stability and technology commercialization efforts. As Halozyme continues its focus on developing transformative therapies, Ramsay's extensive experience within the biotechnology sphere positions him uniquely to guide the financial aspects of these endeavors, all while the company engages an executive search firm to identify a permanent CFO with specific expertise in capital markets and strategic management.

Halozyme is renowned for its innovative solutions, particularly through its ENHANZE® drug delivery technology, which has positively impacted over one million patients worldwide. The firm partners with major pharmaceutical companies like Roche and Takeda to optimize drug delivery systems, enhancing patient experiences and treatment outcomes. As they seek a permanent CFO, Ramsay’s interim leadership could serve to not only maintain financial oversight but also offer innovative strategies that align with Halozyme’s commitment to improving healthcare solutions.

In the broader context, Halozyme's leadership transition reflects the dynamic nature of the biotechnology industry, where the ability to adapt to changes in leadership is pivotal. The quest for a permanent CFO signifies the company’s commitment to fortifying its executive team as it continues to leverage its robust drug delivery technology platform in revolutionizing patient treatment paradigms. With Ramsay at the financial helm, Halozyme is poised to advance its ongoing projects and strategic objectives during this transitional phase.